
    
      Pt. 1 is a 12-week randomized, double-blind, active-control, parallel-group, multi-center
      global study. The primary end point is 75% improvement from baseline according to the
      Psoriasis Area and Severity Index (PASI-75). Comparing CHS-0214 to Enbrel for efficacy and
      safety at a dosage of 50mg subcutaneous (Sc) twice weekly.

      Pt. 2 is a 40-week randomized, double-blind, active-control, parallel-group, multi-center
      global study where CHS-0214 and Enbrel dosage is reduced to 50mg Sc weekly for maintenance.
    
  